Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DOCS Stock Forecast 2026-2027
$20.59
Current Price
$3.77B
Market Cap
Buy 10
Hold 13
Sell 0
Wall St Analyst Ratings
Distance to DOCS Price Targets
+104.0%
To High Target of $42.00
+16.6%
To Median Target of $24.00
-12.6%
To Low Target of $18.00
DOCS Price Momentum
-3.8%
1 Week Change
-19.9%
1 Month Change
-65.0%
1 Year Change
-53.5%
Year-to-Date Change
-73.1%
From 52W High of $76.51
+20.1%
From 52W Low of $17.15
📊 TOP ANALYST CALLS
Did DOCS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Doximity is one of their latest high-conviction picks.
Latest DOCS Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, DOCS has a neutral consensus with a median price target of $24.00 (ranging from $18.00 to $42.00). The overall analyst rating is Buy (7.4/10). Currently trading at $20.59, the median forecast implies a 16.6% upside. This outlook is supported by 10 Buy, 13 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Stan Berenshteyn at Wells Fargo, suggesting a 12.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DOCS Analyst Ratings
10
Buy
13
Hold
0
Sell
DOCS Price Target Range
Low
$18.00
Average
$24.00
High
$42.00
Current: $20.59
Latest DOCS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DOCS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2026 | Goldman Sachs | David Roman | Neutral | Maintains | $24.00 |
| May 15, 2026 | Barclays | Glen Santangelo | Equal-Weight | Downgrade | $20.00 |
| May 14, 2026 | Leerink Partners | Michael Cherny | Outperform | Maintains | $25.00 |
| May 14, 2026 | Jefferies | Brian Tanquilut | Hold | Downgrade | $19.00 |
| May 14, 2026 | Canaccord Genuity | Richard Close | Buy | Maintains | $30.00 |
| May 14, 2026 | JP Morgan | Alexei Gogolev | Neutral | Maintains | $28.00 |
| May 14, 2026 | Goldman Sachs | David Roman | Neutral | Maintains | $24.00 |
| May 14, 2026 | Truist Securities | Jailendra Singh | Hold | Reiterates | $19.00 |
| May 14, 2026 | Wells Fargo | Stan Berenshteyn | Equal-Weight | Downgrade | $18.00 |
| May 14, 2026 | BMO Capital | Sean Dodge | Market Perform | Maintains | $20.00 |
| May 14, 2026 | Mizuho | Steven Valiquette | Neutral | Maintains | $26.00 |
| May 14, 2026 | Morgan Stanley | Ricky Goldwasser | Overweight | Maintains | $35.00 |
| May 14, 2026 | BTIG | David Larsen | Neutral | Downgrade | $N/A |
| May 14, 2026 | Keybanc | Scott Schoenhaus | Sector Weight | Downgrade | $N/A |
| May 14, 2026 | Needham | Ryan MacDonald | Buy | Maintains | $27.00 |
| May 14, 2026 | Baird | Vikram Kesavabhotla | Neutral | Downgrade | $18.00 |
| May 11, 2026 | Wells Fargo | Stan Berenshteyn | Overweight | Maintains | $32.00 |
| Apr 20, 2026 | Truist Securities | Hold | Downgrade | $N/A | |
| Apr 16, 2026 | B of A Securities | Buy | Maintains | $N/A | |
| Apr 13, 2026 | Keybanc | Overweight | Maintains | $N/A |
Doximity Inc. (DOCS) Competitors
The following stocks are similar to Doximity based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Doximity Inc. (DOCS) Financial Data
Doximity Inc. has a market capitalization of $3.77B with a P/E ratio of 21.1x. The company generates $644.86M in trailing twelve-month revenue with a 30.4% profit margin.
Revenue growth is +5.1% quarter-over-quarter, while maintaining an operating margin of +21.6% and return on equity of +19.3%.
Valuation Metrics
Market Cap
$3.77B
Enterprise Value
$3.05B
P/E Ratio
21.1x
PEG Ratio
-0.3x
Price/Sales
5.9x
Growth & Margins
Revenue Growth (YoY)
+5.1%
Gross Margin
+86.7%
Operating Margin
+21.6%
Net Margin
+30.4%
EPS Growth
-69.4%
Financial Health
Cash/Price Ratio
+19.9%
Current Ratio
6.1x
Debt/Equity
1.1x
ROE
+19.3%
ROA
+11.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Doximity Inc. (DOCS) Business Model
About Doximity Inc.
What They Do
Digital platform for U.S. medical professionals.
Business Model
Doximity generates revenue through subscription services, advertising, and partnerships with healthcare organizations. The platform offers tools for telehealth, secure collaboration, and career management, catering to the needs of medical professionals and improving their workflow efficiency.
Additional Information
Founded in 2010 and based in San Francisco, Doximity serves over 80% of physicians and 50% of nurse practitioners in the U.S. It is pivotal in healthcare technology, enhancing clinician productivity and reducing administrative burdens.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
880
CEO
Mr. Jeffrey A. Tangney
Country
United States
IPO Year
2021
Website
www.doximity.comDoximity Inc. (DOCS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
OPRX and DOCS are betting big on AI-driven healthcare engagement as cautious pharma spending pressures near-term growth.
May 28, 2026
By Shivangi Deora
Analyst Blog
Latest News
Quick Summary
Pomerantz LLP is investigating claims for Doximity, Inc. (NYSE: DOCS) investors. Interested parties can contact Danielle Peyton for more information.
Why It Matters
Pomerantz LLP's investigation into Doximity may signal potential legal issues or financial mismanagement, impacting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
DOCS Investors Have Opportunity to Join Doximity, Inc. Fraud Investigation with the Schall Law Firm
4 days ago
Quick Summary
Doximity, Inc. investors can participate in a fraud investigation led by the Schall Law Firm, as announced in a recent Business Wire release.
Why It Matters
The announcement of a fraud investigation into Doximity, Inc. may indicate potential legal and financial risks, impacting stock performance and investor confidence in the company.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
OPRX and DOCS are heavily investing in AI-driven healthcare engagement amid challenges from cautious spending in the pharmaceutical sector affecting short-term growth.
Why It Matters
AI-driven healthcare engagement may enhance efficiency and patient outcomes, potentially leading to revenue growth for OPRX and DOCS amid current spending pressures in pharma.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Doximity Stock Just Got Crushed. Is This a Rare Chance to Buy a High-Quality Growth Company on Sale?
13 days ago
Quick Summary
Investors are wary of AI potentially replacing Doximity's medical solutions, but the company's strong ecosystem and regulatory complexities may provide stability.
Why It Matters
Concerns over AI replacing Doximity's solutions may affect stock sentiment, but its robust ecosystem and regulatory barriers could mitigate disruption risks, influencing long-term value.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Doximity, Inc. (NYSE: DOCS) will present at the William Blair Growth Stock Conference on June 2, 2026, at 4:40 p.m. Central Time. The company serves over 85% of U.S. physicians.
Why It Matters
Doximity's CEO presentation at a prominent growth conference signals potential insights into company strategy and performance, influencing investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Healthcare AI stocks have declined between 30% to 65% in 2026, despite ongoing advancements in their underlying technologies.
Why It Matters
The steep decline in healthcare AI stocks despite platform advancements signals potential undervaluation, presenting opportunities for investors to capitalize on future growth.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
Frequently Asked Questions About DOCS Stock
What is Doximity Inc.'s (DOCS) stock forecast for 2026?
Based on our analysis of 16 Wall Street analysts, Doximity Inc. (DOCS) has a median price target of $24.00. The highest price target is $42.00 and the lowest is $18.00.
Is DOCS stock a good investment in 2026?
According to current analyst ratings, DOCS has 10 Buy ratings, 13 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.59. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DOCS stock?
Wall Street analysts predict DOCS stock could reach $24.00 in the next 12 months. This represents a 16.6% increase from the current price of $20.59. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Doximity Inc.'s business model?
Doximity generates revenue through subscription services, advertising, and partnerships with healthcare organizations. The platform offers tools for telehealth, secure collaboration, and career management, catering to the needs of medical professionals and improving their workflow efficiency.
What is the highest forecasted price for DOCS Doximity Inc.?
The highest price target for DOCS is $42.00 from at , which represents a 104.0% increase from the current price of $20.59.
What is the lowest forecasted price for DOCS Doximity Inc.?
The lowest price target for DOCS is $18.00 from Stan Berenshteyn at Wells Fargo, which represents a -12.6% decrease from the current price of $20.59.
What is the overall DOCS consensus from analysts for Doximity Inc.?
The overall analyst consensus for DOCS is neutral. Out of 16 Wall Street analysts, 10 rate it as Buy, 13 as Hold, and 0 as Sell, with a median price target of $24.00.
How accurate are DOCS stock price projections?
Stock price projections, including those for Doximity Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 3:57 AM UTC